A jury in St. Louis, Missouri, has ruled in favor of Mead Johnson, the maker of Enfamil, in a lawsuit over its preterm baby formula. The lawsuit, brought by an Illinois mother, claimed that the formula caused her daughter to develop necrotizing enterocolitis, a dangerous bowel disease that affects premature newborns.
Background of the Case
The mother, Cadence Collins, alleged that Mead Johnson’s specialized formula for preterm babies was to blame for her daughter’s condition. However, the jury rejected these claims, siding with Mead Johnson. The company has maintained that its products do not cause necrotizing enterocolitis and that the benefits of breast milk in preventing the disease have long been known to clinicians.
The case is one of nearly 1,000 similar lawsuits filed against Mead Johnson and Abbott Laboratories, which makes Similac formulas. More than 700 of these cases are centralized in an Illinois federal court, with others pending in state courts, including Missouri and Pennsylvania.
Mead Johnson has stated that it strongly rejects any assertion that its specialized preterm hospital nutrition products cause necrotizing enterocolitis. The company’s position is that while breast milk protects against the bowel disease, its formulas do not cause it.
Implications of the Verdict
The verdict is significant, as it may impact the outcome of other similar lawsuits. Attorneys for Collins have expressed disagreement with the verdict and are evaluating all options on behalf of their client. The case highlights the ongoing debate over the safety and efficacy of preterm baby formulas and the importance of breast milk in preventing necrotizing enterocolitis.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
